Belite Bio, Inc

NASDAQ:BLTE

Biotechnology

Healthcare
$156.23 +0.31%

+$0.46 today

Market cap
$6.29B
Beta
-1.24
P/E (TTM)
-65.9
EPS (TTM)
-$2.26
52W Low $56.10High $200.00

Volume 0.09M

Average 0.17M

BLTE Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Belite Bio, IncNASDAQ: BLTE

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash outflow grows to $0

Q2 FY2026 net change in cash was $0, compared with $0 a year earlier. Trailing-twelve-month net change in cash was -$157.03K. Over 3 fiscal years it compounded at +135.0% a year.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$39.26K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
$321.26M+668.8% YoY
LTMJun 2026
-$157.03K— YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+668.8%——
3-year CAGR+135.0%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
321.26M USD
Year-over-year change
+668.8%

Net Change in Cash vs competitors

How BLTE compares with its peers on the latest reported figures

  • BLTE's LTM Jun 2026 net change in cash of $157.03K is the smallest of the 6 companies compared; the peer median is $5.94M.
  • Over three fiscal years its annual growth of +135.0% compares with a peer median of +12.5%.
BLTE Competitors Peer median
Net Change in Cash for BLTE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KLRSKalaris Therapeutics IncLTM Mar 2026$66.54M ———
IRDOpus Genetics, Inc.LTM Mar 2026$18.17M +438.4%-6.6%151.6%
KODKodiak Sciences Inc.LTM Sep 2026$14.4M +111.4%——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$7.45M -96.0%—97.8%
OCGNOcugen, Inc.LTM Mar 2026$5.94M -150.6%+31.5%133.0%
BLTEBelite Bio, IncLTM Jun 2026$157.03K —+135.0%—
Peer median (excluding BLTE) $5.94M+7.7%+12.5%133.0%

Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.67M)(12.65M)(31.63M)(36.14M)(77.61M)
Depreciation & Amortization30K198K399K449K464K
Deferred Income Tax0(1.91M)(4.69M)00
Stock-Based Compensation1.53M1.48M3.82M8.99M38.92M
Change in Working Capital640K(491K)(2.43M)1.13M2.55M
Accounts Receivables0(32K)(72K)74K(66K)
Inventory00000
Accounts Payables00000
Other Working Capital640K(459K)(2.36M)1.06M2.62M
Other Non-Cash Items(8K)1.91M4.69M(3.66M)(1.31M)
Operating Cash Flow(7.47M)(11.46M)(29.84M)(29.23M)(36.99M)
Capital Expenditures(74K)(394K)(63K)(151K)(178K)
Acquisitions (Net)18K0000
Purchases of Investments000(188.27M)(451.99M)
Sales of Investments00077.84M147.07M
Other Investing Activities000(35K)0
Investing Cash Flow(56K)(394K)(63K)(110.57M)(305.11M)
Debt Repayment00000
Common Stock Issued(583K)37.99M77.19M42.24M292.86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(1.03M)(1.23M)41.36M370.37M
Financing Cash Flow(583K)36.96M75.96M83.6M663.23M
Effect of Forex Changes(161K)(366K)9K(269K)117K
Net Change in Cash(8.27M)24.75M46.07M(56.48M)321.26M
Free Cash Flow(7.55M)(11.85M)(29.9M)(29.39M)(37.17M)

Belite Bio, Inc

NASDAQ:BLTE

Intrinsic Alpha fair value

Locked

Current Price

$156.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.